Seqirus receives FDA approval of Afluria Quadrivalent (influenza vaccine) for people six months of age and older in the U.S.

17 October 2018 - Seqirus today announced the U.S. FDA has approved Afluria Quadrivalent (influenza vaccine) for use in people ...

Read more →

Valneva announces FDA approval of accelerated Ixiario vaccination schedule

5 October 2018 - Valneva announced today that the U.S. FDA has approved an alternate Ixiaro immunisation schedule of two doses ...

Read more →

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

5 October 2018 - The U.S. FDA today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) ...

Read more →

Statement by FDA Commissioner on preparations for the upcoming flu season and vaccinations

27 September 2018 - This week marks the official start of “flu season” for 2018-2019.  ...

Read more →

Pfizer granted FDA breakthrough therapy designation for 20 valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults aged 18 years ands older

20 September 2018 - Breakthrough therapy designation designed by FDA to expedite the development and review of drugs and vaccines which ...

Read more →

Sellas receives fast track designation from FDA for galinpepimut-S for the treatment of patients with multiple myeloma

20 July 2018 - Sellas Life Sciences today announced that the U.S. FDA has granted fast track designation to the Company’s ...

Read more →

FDA grants priority review to Merck’s supplemental biologics license application for Gardasil 9 in women and men ages 27 to 45 for the prevention of certain HPV-related cancers and diseases

13 June 2018 - Merck today announced that the U.S. FDA has accepted for review a new supplemental biologics license application ...

Read more →

FDA grants PaxVax fast track designation for its Chikungunya vaccine

4 May 2018 - There are no licensed vaccines for chikungunya prevention and no specific treatments. ...

Read more →

Pfizer granted FDA breakthrough therapy designation for Trumenba (meningococcal Group B vaccine) for the prevention of invasive meningococcal B disease in children aged 1 to 9 years

23 April 2018 - Pfizer today announced that Trumenba (meningococcal Group B vaccine) received breakthrough therapy designation from the U.S. FDA ...

Read more →

Statement from FDA Commissioner on FDA’s ongoing efforts to help improve effectiveness of influenza vaccines

26 February 2018 - The current influenza season has been especially difficult, causing widespread illness that has affected all fifty ...

Read more →

GSK’s meningitis B vaccine Bexsero receives breakthrough therapy designation from US FDA for prevention of invasive meningococcal disease in children 2-10 years of age

7 February 2018 - GlaxoSmithKline today announced that it has received breakthrough therapy designation from the U.S. FDA for its meningitis ...

Read more →

Takeda's Zika vaccine gets U.S. FDA's 'fast track' status

30 January 2018 - Japan’s Takeda Pharmaceutical Co Ltd said on Monday the U.S. FDA had granted ‘fast track’ status to ...

Read more →

GSK receives FDA approval for expanded indication for Fluarix Quadrivalent (influenza vaccine) for persons 6 months and older

11 January 2018 - GSK announced today it has received approval from the US FDA's Center for Biologics Evaluation and Research ...

Read more →

Dynavax announces FDA approval of Heplisav-B for prevention of hepatitis B in adults

9 November 2017 - First and only two-dose vaccine in United States for prevention of hepatitis B in adults. ...

Read more →

New shingles vaccine endorsed over competitor by expert panel, a boost for GSK

25 October 2017 - The expert panel that helps guide U.S. vaccination policy has voted to give a preferential recommendation ...

Read more →